Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

MacKenzie George

Physician Assistant, Medical Kalispell, MT Physician Assistant

NPI 1750826061 CMS profile 10645911

175 Commons Loop Ste 300, Kalispell, MT 59901

Open in the dashboard

General payments

$9,324

322 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, MacKenzie George of Kalispell, MT is reported in the CMS Open Payments database as having received $9,324 across 322 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,710 81
2024 General $3,027 85
2023 General $1,892 75
2022 General $1,125 50
2021 General $571 31

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • MacKenzie George
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to MacKenzie George were reported at $2,710. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year MacKenzie George Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $571 $156 $41–$563 $132
2022 $1,125 $185 $55–$649 $149
2023 $1,892 $199 $58–$717 $160
2024 $3,027 $206 $62–$740 $164
2025 $2,710 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,207 84 payments
  2. Novartis Pharmaceuticals Corporation $1,447 47 payments
  3. Lilly USA, LLC $906 42 payments
  4. Sun Pharmaceutical Industries Inc. $858 2 payments
  5. UCB, Inc. $824 25 payments
  6. E.R. Squibb & Sons, L.L.C. $746 30 payments
  7. Janssen Biotech, Inc. $695 22 payments
  8. Amgen Inc. $618 29 payments
  9. Regeneron Healthcare Solutions, Inc. $339 13 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $178 3 payments
  11. Other $506 25 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $7,404 316 payments
  2. Consulting Fee $1,550 2 payments
  3. Education $370 4 payments
Products named General payments · program years 2021–2025
  1. RINVOQ $1,451 36 payments
  2. ILUMYA $858 2 payments
  3. COSENTYX Dermatology $772 30 payments
  4. Bimzelx $767 21 payments
  5. SOTYKTU $746 30 payments
  6. TALTZ $720 40 payments
  7. TREMFYA $705 23 payments
  8. Otezla $618 29 payments
  9. SKYRIZI $571 35 payments
  10. COSENTYX Immunology $556 14 payments
  11. Other $2,274 117 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

555

Median for Physician Assistant: 241

Drug cost

$712,907

Median for Physician Assistant: $4,110

Branded share of claims

26.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Skyrizi Pen Risankizumab-Rzaa Brand 11 $214,250
Taltz Syringe Ixekizumab Brand 16 $135,792
Dupixent Pen Dupilumab Brand 29 $106,765
Otezla Apremilast Brand 18 $89,852
Rinvoq Upadacitinib Brand 12 $78,654
Dupixent Syringe Dupilumab Brand 20 $77,184
Clobetasol Propionate Generic 56 $3,173
Valacyclovir Valacyclovir Hcl Brand 29 $903
Clindamycin Phosphate Generic 31 $898
Ketoconazole Generic 54 $839

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 50 billing codes

Paid by Medicare

$95,763

Medicare's payments for the services billed

Medicare patients

586

Average age 73

Services billed

2,670

346 women, 240 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 57%
Arthritis 42%
Depression 16%
Cancer 15%
Osteoporosis 15%
Ischemic heart disease 14%
Diabetes 13%
Chronic kidney disease 12%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ILUMYA
  • Sun Pharmaceutical Industries Inc. $786
$786 — —
Bimzelx
  • UCB, Inc. $480
$480 — —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $366
$366 — —
COSENTYX
  • Novartis Pharmaceuticals Corporation $231
$231 — —
TREMFYA
  • Janssen Biotech, Inc. $178
$178 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

322 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Montana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record